With a new, highly experienced and commercially focused management team, CelLBxHealth is focused on accelerating the commercial rollout of its Parsortix circulating tumour cell (CTC) capture platform and related services. To facilitate these commercialisation efforts and to assist in a near-term corporate restructure, CelLBxHealth has conditionally raised gross proceeds of £6.8m through a proposed equity placing with the potential to raise a further £1.0m through a retail and open offer. In para ....
